U.S. markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7800+0.0010 (+0.13%)
At close: 04:00PM EDT
0.7800 0.00 (0.00%)
After hours: 05:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Outside Bar (Bullish)

Outside Bar (Bullish)

Previous Close0.7790
Bid0.7660 x 1400
Ask0.8199 x 800
Day's Range0.7678 - 0.8092
52 Week Range0.6800 - 19.8700
Avg. Volume336,738
Market Cap27.353M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SPRO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Spero Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

    Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen Trial of SPR206 Expected in 3Q 2023 Continued Engagement with FDA is Expected to Provide Key Insights into the Path Forward for Tebipenem HBr Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announc

  • GlobeNewswire

    Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

    CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565. The audio webcast can be accessed under “Events and Pr

  • GlobeNewswire

    Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

    CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis. The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022. In th